Project profile — Canadian HIV Vaccine Initiative - Large-Team Grants

• Africa, regional (100.00%)

• Population Policies/Programmes And Reproductive Health: STD control including HIV/AIDS (13040) (100.00%)

• Gender equality (not targeted)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• ICT as a tool for development (not targeted)

The goal of the Large-Team Grants program under the Discovery and Social Research component of the Canadian HIV Vaccine Initiative (CHVI) is to make a significant contribution to HIV vaccine discovery and social research, and to train the next generation of HIV vaccine researchers. Funded teams are expected to strengthen links between researchers in Canada and those in low- and middle-income countries (LMIC) to increase integration and facilitate the sharing of research data and knowledge. The program, as part of the component, makes a significant contribution to research and research capacity focussed on: the discovery of HIV vaccines and related issues, and social and behavioural issues around HIV vaccines. Teams co-led by Canadian and LMIC researchers receive support for projects that build on their relevant skills and expertise and align with the Global Enterprise’s Scientific Strategic Plan.

N/A

Results achieved as of March 2013 include: nine collaborative teams of Canadian and low- and middle-income country researchers received funding to support the development of Large Team Grant - HIV/AIDS Vaccine Discovery and Social Research program applications; five teams were awarded multi-year funding and are conducting HIV/AIDS vaccine discovery and social research; a stronger partnership between Canadian and African research partners was developed; new collaborations have been established between the research teams; synergies and complementarities within the program, with other Canadian HIV Vaccine Initiative components, and other global efforts were strengthened.

• Proactive disclosure